Breakthrough Medical Discovery: Can Therapeutic Angiogenesis Treat Heart Disease, Strokes, Peripheral Artery Disease, Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Depression and more?
Over 50% of all deaths in adults worldwide are the result of insufficient blood flow due to some form of obstruction. Over 75 human diseases result from a lack of blood flow to a tissue or organ, including heart disease, the number one cause of death in the world. Stroke also results from a lack of blood flow and is the number three killer in the world.
Recent medical discoveries from imaging blood flow in the brain are showing that “vascular disruption” is an initiating cause of Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis, chronic depression and other neurodegenerative diseases. Many of these diseases are diseases of aging and as you age, you have less blood flow in your brain. If your memory neurons in your brain are not receiving sufficient blood to provide them oxygen, nutrients and the removal of waste products for their proper functioning then they do not perform properly. Many medical researchers believe that the lack of blood flow in the brain is the cause of Alzheimer’s disease.
Therapeutic Angiogenesis is the medical therapy of utilizing a bio-manufactured human molecule that triggers “angiogenesis”. Angiogenesis is the biological process of growing new blood vessels. Your body does this when you scrape your elbow. Your body makes the very same molecule we are utilizing in our clinical trials. Our drug is a growth factor which signals your body to regenerate (repair) the wounded area, including new skin, new nerves, new sweat glands and new blood vessels; this molecule is how you have healed yourself thousands of times in your life.
This is where Zhittya Genesis Medicine Inc. (ZGM) comes in. Zhittya is a Biopharmaceutical company, developing for FDA approval, a biological drug which triggers angiogenesis and neurogenesis. Does ZGM have possible treatment for diseases that kill over 50% of the people in the world? Register now and find out in Zhittya’s presentation at the GCFF Virtual Conference on September 10th.
For more information go to Zhittya’s website: zgm.care
* The medical science and the clinical evidence. There is no product or service for sale, since our pharmaceutical has not yet been approved by the US FDA.
Jack Jacobs, Ph.D.
President and Chief Scientific Officer
Dr. Jacobs received his BS degree from Davidson College and a Ph.D. in molecular biology from Washington University, St. Louis. He has been involved in the healthcare industry for over 25 years and has extensive expertise in supervising drug manufacturing operations and the design and implementation of preclinical animal trials and US FDA-authorized clinical trials. He started a new department of Biological Chemistry at Merck and for 15 years worked with Mr. Montano as CardioVascular BioTherapeutics’ Chief Scientific Officer where he oversaw FDA-authorized clinical trials in which FGF-1 was tested in a number of medical indications, including coronary artery disease, diabetic foot ulcers and peripheral artery disease. He also oversaw the manufacturing of clinical lots of FGF-1 that were used in those clinical studies.
September 10th, 2020 Thursday
8:30am – 1:30pm PST (11:30am – 4:30 EST)
Covering the healthcare, technology, fintech and cannabis sectors the GCFF Virtual Conference – Investing in Innovation will provide its participants with access to exciting investment opportunities that are at the cusp of value growth. The bilingual online event will feature 12 public and private company presentations and will broadcasted in both English and Mandarin Chinese channels. Register for our virtual event today!